Introduction

One of the most common questions manufacturers ask under EU MDR is deceptively simple:
If we already have a Post-Market Surveillance (PMS) system, do we really need Post-Market Clinical Follow-up (PMCF)?

The short answer is: PMS is always required. PMCF is conditionally required—but never optional without justification.

This distinction has become a major source of Notified Body (NB) observations, delays, and nonconformities. Many manufacturers either underestimate PMCF or assume it applies only to high-risk or implantable devices. Under EU MDR 2017/745, that assumption no longer holds.

This blog explains the true regulatory expectation, how PMS and PMCF differ, when PMCF is required, and how to justify its absence in a defensible way.

Understanding PMS Under EU MDR

What Is PMS?

Post-Market Surveillance (PMS) is a systematic process to actively and continuously collect, analyse, and evaluate data about a device once it is placed on the market.

Under Article 83 of EU MDR, PMS is mandatory for all medical devices, regardless of class.

PMS is designed to:

• Monitor clinical safety and performance
• Identify emerging risks
• Detect trends and signals
• Confirm the benefit–risk profile throughout the device lifecycle

PMS is not a passive complaint-handling system. It is an active surveillance framework.

Typical PMS Data Sources

PMS commonly includes:

• Customer complaints and feedback
• Vigilance and incident reports
• Trend reporting
• Literature monitoring
• Sales and usage data
• Field safety corrective actions (if any)

PMS data feeds directly into:

• Risk management (ISO 14971)
• Clinical evaluation updates
• Periodic Safety Update Reports (PSUR)
• PMCF planning decisions

What Is PMCF?

PMCF Is a Subset of PMS

Post-Market Clinical Follow-up (PMCF) is not a separate obligation—it is a clinical component within PMS.

According to Annex XIV, Part B of EU MDR, PMCF is a proactive process to:

• Continuously confirm clinical safety and performance
• Reduce residual clinical uncertainties
• Verify clinical benefits in real-world use
• Detect rare or long-term risks

While PMS often reacts to available data, PMCF actively generates new clinical data.

Common PMCF Activities

PMCF may include:

• PMCF clinical investigations
• Registry studies
• User or patient surveys
• Structured feedback from healthcare professionals
• Analysis of real-world clinical outcomes
• Extended follow-up of pre-market studies

PMCF does not automatically mean a new clinical trial—but it does require structured clinical justification.

When Is PMCF Really Required?

The Regulatory Principle

EU MDR does not state that PMCF is mandatory for every device. Instead, it requires manufacturers to:

Implement PMCF unless it can be duly justified that PMCF is not necessary.

This shifts the burden from “Do we need PMCF?” to:
“Can we defend why PMCF is not required?”

PMCF Is Expected When:

Notified Bodies typically expect PMCF when one or more of the following apply:

• Novel or innovative technology
• Limited pre-market clinical data
• New indications or expanded intended use
• Long-term or repeated use
• Implantable or invasive devices
• Higher-risk devices (Class IIa, IIb, III)
• Residual clinical uncertainties
• Identified gaps in clinical evidence
• New safety signals from PMS

In these cases, PMS alone is rarely considered sufficient.

Is PMCF Required for Class I Devices?

This is one of the most misunderstood areas.

Class I devices are not automatically exempt from PMCF.

PMCF may still be expected if:

• The device has limited clinical literature
• The intended use involves clinical claims
• The device is used repeatedly or long term
• PMS data is insufficient to confirm performance

However, for well-established, low-risk Class I devices, PMCF may be justifiably not required—but only with strong documentation.

How to Justify “PMCF Not Required”

If PMCF is not performed, EU MDR requires a clear, evidence-based justification.

A defensible justification typically includes:

• Long history of safe clinical use
• Sufficient and current clinical literature
• Robust PMS data with no safety signals
• Well-understood technology
• No residual clinical uncertainties
• Alignment with risk management conclusions

The justification must be documented in:

• The PMCF Evaluation Report
• The Clinical Evaluation Report (CER)
• The PMS Report / PSUR

Simply stating “PMCF not applicable” is a guaranteed NB finding.

Common Regulatory Mistakes That Cause PMCF-Related Delays

Notified Bodies frequently raise observations due to:

❌ No PMCF plan or evaluation
❌ PMCF marked “not required” without justification
❌ No linkage between PMS, PMCF, and CER
❌ Outdated clinical evidence
❌ PMS treated as complaint handling only
❌ Risk management not updated with post-market data

These issues often trigger major nonconformities, even for low-risk devices.

PMS, PMCF, and CER Must Work Together

Under EU MDR, clinical evaluation is a lifecycle process.

This means:

• PMS identifies trends and signals
• PMCF addresses clinical uncertainties
• CER integrates all clinical evidence
• Risk management is updated accordingly

If these elements are not aligned, regulators view the clinical strategy as fragmented and weak.

What Notified Bodies Really Look For

During review, NBs focus less on whether PMCF exists and more on:

• Regulatory reasoning
• Risk-based decision-making
• Transparency
• Consistency across documents

They ask:

• Why was PMCF performed—or not performed?
• What clinical questions remain unanswered?
• How are residual risks monitored?
• How does post-market data support benefit–risk acceptability?

Strong answers reduce questions. Weak justification extends timelines.

Final Thoughts: PMCF Is About Evidence, Not Formality

PMS and PMCF are not checkboxes. They are tools to continuously confirm that a device remains safe and performs as intended in real-world use.

Under EU MDR:

• PMS is mandatory
• PMCF is conditional
• Justification is non-negotiable

Manufacturers who plan post-market strategy early—and document it clearly—move through regulatory review faster and with fewer surprises.

Compliance is not about doing more.
It is about doing what is justified, and justifying what is not done.